Get ready for a game-changer in the world of cell and gene therapies! PHCbi, a global leader in laboratory solutions, has just unveiled its latest innovation: LiCellGrow™. This cutting-edge system is set to revolutionize the way we approach the production of advanced therapies, offering a more efficient and high-quality process.
But here's where it gets exciting: LiCellGrow™ is designed to tackle the challenges faced by therapy developers, ensuring a consistent and reliable manufacturing process. With its unique features, it promises to enhance efficiency, reduce costs, and improve the overall quality of cell and gene therapies.
One of the key strengths of LiCellGrow™ lies in its ability to monitor and control culture conditions in real-time. By continuously measuring glucose and lactate concentrations, two vital indicators of cell metabolism, the system can automatically adjust the culture medium, creating an optimal environment for cell growth. This level of precision and control is a game-changer, especially when dealing with complex manufacturing processes.
And this is the part most people miss: the system's single-use design ensures aseptic conditions, reducing the risk of contamination. With automated measurements, the need for manual sampling is eliminated, further enhancing the reliability and reproducibility of cell culture.
PHCbi's commitment to innovation doesn't stop there. Under its Value Creation Plan 2027, the company is focused on developing solutions to enhance efficiency and reduce costs in CGT manufacturing. LiCellGrow™ builds upon the success of its predecessor, LiCellMo™, a live-cell metabolic analyzer, taking CGT manufacturing to the next level.
The system's key features include automated control and optimization of culture conditions, ensuring a consistent and optimal environment for cell growth. Additionally, its single-use design and compatibility with standard CO₂ incubators make it an accessible and reliable solution for researchers and healthcare providers worldwide.
Chikara Takauo, Director of PHC Corporation, expressed excitement about the launch, highlighting LiCellGrow™'s potential to address common challenges in the field. With its focus on quality, cost, and scalability, LiCellGrow™ is poised to become a game-changer in the adoption of advanced therapy options for hard-to-treat conditions.
So, what do you think? Is LiCellGrow™ the breakthrough we've been waiting for in cell and gene therapy manufacturing? Share your thoughts and let's spark a discussion on the future of healthcare innovation!
